{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:43:46Z","timestamp":1773866626967,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1136\/ijgc-00009577-200511000-00005","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T14:30:50Z","timestamp":1717079450000},"page":"1035-1041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase II study of fixed dose rate gemcitabine in patients with relapsed m\u00fcllerian tumors"],"prefix":"10.1016","volume":"15","author":[{"given":"R.T.","family":"Penson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.V.","family":"Seiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"A.F.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Willman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0001","first-page":"8","article-title":"Cancer statistics","volume":"49","author":"Landis","year":"1999","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0002","first-page":"340","article-title":"Chemotherapy of advanced ovarian cancer","volume":"25","author":"McGuire","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.4-4-293","article-title":"Progress in gynecologic oncology","volume":"4","author":"Penson","year":"1999","journal-title":"Oncologist"},{"issue":"Suppl. 1","key":"10.1136\/ijgc-00009577-200511000-00005_bb0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0923-7534(20)31484-8","article-title":"Gemcitabine in the treatment of ovarian cancer","volume":"10","author":"Hansen","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0005","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (29,29-difluorodeoxycytidine) in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0006","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0007","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1023\/A:1008364327684","article-title":"Phase II study of gemcitabine in ovarian cancer","volume":"10","author":"von Minckwitz","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0008","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"issue":"5 Suppl. 10","key":"10.1136\/ijgc-00009577-200511000-00005_bb0009","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","article-title":"Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study","volume":"10","author":"Grunewald","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0011","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose-intense gemcitabine: thirtyminute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma","volume":"21","author":"Tempero","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0012","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1259\/bjr.75.899.750903","article-title":"Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria","volume":"75","author":"Trillet-Lenoir","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0013","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.2002.20.5.1158","article-title":"Is there a \u2018best\u2019 choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?","volume":"20","author":"Cannistra","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1 Suppl. 1","key":"10.1136\/ijgc-00009577-200511000-00005_bb0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/sonc.2002.31588","article-title":"Second-line treatment of ovarian cancer with single-agent gemcitabine","volume":"29","author":"Markman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0016","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00000421-199910000-00005","article-title":"Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum","volume":"22","author":"Silver","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0017","article-title":"A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer","author":"Underhill","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0018","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/00001813-200109000-00002","article-title":"Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer","volume":"12","author":"Underhill","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1136\/ijgc-00009577-200511000-00005_bb0019","article-title":"A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian carcinomas","author":"Kudelka","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"2 Suppl. 7","key":"10.1136\/ijgc-00009577-200511000-00005_bb0020","first-page":"S7-50","article-title":"Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer","volume":"24","author":"Shepherd","year":"1997","journal-title":"Semin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24150724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24150724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-00009577-200511000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:03:54Z","timestamp":1753232634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24150724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":20,"aliases":["10.1111\/j.1525-1438.2005.00482.x"],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1048891X24150724"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200511000-00005","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of fixed dose rate gemcitabine in patients with relapsed m\u00fcllerian tumors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200511000-00005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2005 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}